Cancer Clinical Trials

Contact Cancer Clinical Trials

For more information, call 484-628-8193.

McGlinn Cancer Institute has an active clinical trials program - only the most promising treatment, prevention, and risk assessment studies are approved for our patients.

Clinical trials give our cancer patients options that reach beyond standard treatment and provide a way to discover new therapies to combat cancer.

Eligible patients have the opportunity to voluntarily participate in clinical trials.

About Clinical Trials

Clinical trials are made available to patients through our research affiliations with:

  • The Sidney Kimmel Cancer Center at Jefferson
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • National Surgical Adjuvant and Bowel Project (NSABP)
  • Radiation Treatment Oncology Group (RTOG)
  • Gynecologic Oncology Group (GOG)
  • Eastern Cooperative Oncology Group (ECOG)
  • The American College of Surgeons Oncology Group (ACoSOG)

Institutional Review Board

All clinical trials approved for our patients are carefully reviewed by our Institutional Review Board (IRB). This committee reviews and approves all clinical research that takes place at Reading Hospital.

The IRB's purpose is to ensure patient rights and safety; Federal Regulations, State Law and Hospital Policy guide the decisions of the IRB.

The IRB is a group made up of 16 members of varying backgrounds including representatives from the medical staff, chaplaincy services, nursing, pharmacy, administration, and the community. The IRB meets monthly to review new research proposals and ongoing studies.

Current Cancer Clinical Trials

Cancer clinical trials are under the direction of Terrence P. Cescon, MD, Principal Investigator. Sub-Investigators are:

  • Medical Oncoloy: Nicole M. Agostino, DO; Patrick J. Colarusso, DO; Daniel A. Forman, DO; Nick C. Leasure, MD; David M. Lu, MD; Simi M. Rai, MD; Erik J. Rupard, MD
  • Gynecologic Oncology: Bernice Robinson-Bennett, MD; John B. Villeneuve, MD
  • Radiation Oncology: Michael L. Haas, MD; Colin T. Murphy, MD; Adam J. T. Smith, MD, PhD

To learn more about any of the Cancer Clinical Trials contact the Protocol Office at 484-628-8193.

Brain

NRG-CC001: A randomized Phase III trial of memantine and whole-brain radiotherapy with or without hippocampal avoidance in patients with brain metastases

The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation plus memantine with the usual whole-brain radiation plus memantine. The hippocampus is a brain structure that is important for memory.

Learn more about the NRG-CC001 trial or call the Protocol Office at 484-628-8193.

Breast

Johns Hopkins-TBCRC 040: Plasma tumor DNA and pathologic complete response in early-stage, high-risk breast cancer

The purpose of this study is to see if it is possible to use blood samples to predict response to treatment in breast cancer patients receiving preoperative (or neoadjuvant) therapy.

Learn more about the Johns Hopkins-TBCRC 040 trial or call the Protocol Office at 484-628-8193.


ECOG-E1Z11: A cohort study to evaluate genetic predictors of aromatase inhibitor musculoskeletal symptoms (AIMSS)

The purpose of this study is to find out what effects, good and/or bad, anastrozole has and whether genetics can help explain the effects of anastrozole. This study only remains open to Asian population.

Learn more about the ECOG-E1Z11 trial or call the Protocol Office at 484-628-8193.



• ADJUVANT (therapy that is given in addition to the primary or initial therapy to maximize its effectiveness)

NRG-BR003: A randomized Phase III trial of adjuvant therapy comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative triple-negative invasive breast cancer

The purpose of this study is to compare the good and bad effects of the chemotherapy drug carboplatin given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.

Learn more about the NRG-BR003 trial or call the Protocol Office at 484-628-8193.


PrECOG-PrE0109: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

The purpose of this study is to compare any good and bad effects of taking two years of Palbociclib in combination with standard anti-hormone therapy to using standard anti-hormone therapy alone and to evaluate the likelihood of invasive breast cancer returning.

Learn more about the PrECOG-PrE0109 trial or call the Protocol Office at 484-628-8193.


NSABP-B51/RTOG 1304: A randomized phase III clinical trial evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRTin patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy

The purpose of this clinical trial is to study women who have cancer cells in their lymph nodes at the time that the breast cancer is diagnosed and then have chemotherapy before surgery that clears the cancer cells from the lymph nodes. Following surgery, radiation to the breast and lymph nodes will be evaluated against radiation to the breast only.

Learn more about the NSABP-B51/RTOG 1304 trial or call the Protocol Office at 484-628-8193.


Johns Hopkins-J13104: A randomized phase II study of partial breast irradiation and sequential vs. concurrent chemotherapy in women with early stage breast cancer

The purpose of this study is to determine whether giving partial breast irradiation and chemotherapy at the same time (newer method) has the same side effects and outcomes as giving partial breast irradiation and chemotherapy at different times (older method).

Learn more about the Johns Hopkins-J13104 trial or call the Protocol Office at 484-628-8193.



• ADVANCED CANCER

RTOG-1119: Phase II randomized study of whole brain radiotherapy in combination with concurrent lapatinib in patients with brain metastasis from Her2-positive breast cancer

The purpose of this study is to compare the effects of adding lapatinib to standard brain radiation therapy. The study will try to find out whether radiation therapy alone or lapatinib plus radiation therapy is better at safely improving tumor control.

Learn more about the RTOG-1119 trial or call the Protocol Office at 484-628-8193.


ECOG-E2112: A randomized phase III trial of endocrine therapy plus entinostat/placebo in postmenopausal patients with hormone receptor-positive advanced breast cancer

The purpose of this study is find out what effects, both good and bad, an experimental drug called entinostat has on you and your cancer, when given together with the standard hormonal drug treatment, exemestane.

Learn more about the ECOG-E2112 trial or call the Protocol Office at 484-628-8193


NRG-BR001: A phase I study of stereotactic body radiotherapy (SBRT) for the treatment of multiple metastases

The purpose of this study is to test the safety of giving a few, focused, high doses of radiation (commonly referred to as stereotactic body radiotherapy [SBRT]) to all known sites of cancer within your body.

Learn more about the NRG-BR001 trial or call the Protocol Office at 484-628-8193


NRG-BR002: A phase IIR/III trial of standard of care with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligo metastatic breast cancer

The purpose of this study is to test whether treating breast cancer metastases with surgery or high-dose radiation improves survival.

Learn more about the NRG-BR002
trial or call the Protocol Office at 484-628-8193



• NEOADJUVANT (therapy given before the main treatment)/ADJUVANT (therapy that is given in addition to the primary or initial therapy to maximize its effectiveness)

SWOG-S1418/BR006: A randomized phase III trial to evaluate the efficacy and safety of MK-3475 (pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with > 1cm residual invasive cancer or positive lymph nodes (YPN+) after neoadjuvant

The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery.

Learn more about the SWOG-S1418/BR006 trial or call the Protocol Office at 484-628-8193


NRG-NSABP B55: A randomized, double-blinded, parallel group, placebo-controlled multi-center phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with GERMLINE BRCA1/2 mutations and high risk her2-negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

The purpose of this study is to compare the addition of olaparib after the usual treatment of chemotherapy, surgery, and radiation for a certain subset of breast cancer patients.

Learn more about the NRG-NSABP B55 trial or call the Protocol Office at 484-628-8193.

Gastrointestinal

• COLON/RECTAL

NRG-NSABP C-13: A phase III randomized placebo-controlled study evaluating regorafenib following completion of standard chemotherapy for patients with stage III colon cancer

The purpose of this study is to test whether the oral (by mouth) drug regorafenib is effective in reducing the risk of colon cancer recurring after patients have received adjuvant chemotherapy.

Learn more about the NRG-NSABP C-13 trial or call the Protocol Office at 484-628-8193.


NRG-GI002: A phase II clinical trial platform of sensitization utilizing total neoadjuvant therapy (TNT) in rectal cancer

The purpose of this study is to learn if adding an experimental drug, veliparib (also known as ABT-888), to the usual treatment is better than the usual treatment alone. Another purpose of this study is to test the good and bad effects of veliparib when added to the usual treatment.

Learn more about the NRG-GI002 trial or call the Protocol Office at 484-628-8193


MPR1-MPR1: Patient registry and bio-specimen profiling repository

The purpose of MPR-1 is to do genetic tests on samples of tissue, including tumor tissue, and if available, normal tissue, that have already been removed from the patient’s body in a previous surgery. The main purpose of doing tests on these tissue samples is to find genetic changes associated the type of cancer diagnosed. The information from the genetic tests, along with the patient’s health information, will be used to help find an appropriate treatment trial for the patient, if one becomes available.

Learn more about the MPR1-MPR1 trial or call the Protocol Office at 484-628-8193.



• PANCREAS

SWOG-S1505: A randomized phase II study of perioperative MFOLFIRINOX versus gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma

The purpose of this study is to compare the effects of two different combinations of FDA-approved chemotherapy drugs. These two combinations are called MFOLFIRINOX (oxaliplatin, irinotecan, and fluorouracil) and gemcitabine plus nab-paclitaxel.

Learn more about the SWOG-1505 trial
or call the Protocol Office at 484-628-8193.


SWOG-S1513: Randomized phase II study of 2nd line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (VELIPARIB) (NSC-737664) in metastatic pancreatic cancer

The purpose of this study is to compare any good and bad effects of using the investigational drug ABT-888 (Veliparib) with modified FOLFIRI compared to using FOLFIRI alone.

Learn more about the SWOG-S1513 trial or call the Protocol Office at 484-628-8193.


RTOG-0848: A phase III trial evaluating both ERLOTINIB and chemo-radiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma

The purpose of this study is to compare any good and bad effects of using radiation plus a fluoropyrimindine (an FDA-approved chemotherapy drug that may help radiation be more effective) along with usual chemotherapy compared to usual chemotherapy alone.

Learn more about the RTOG-0848 trial or call the Protocol Office at 484-628-8193.


TJU-08D.213: Jefferson Pancreas Tumor Registry (JPTR)

The purpose of this research study is to collect information to determine if pancreas tumors and related conditions tend to occur more frequently in families with a history of the disease and to determine environmental and occupational risk factors to which patients may be exposed.

Learn more about the TJU-08D.213 trial by calling the Protocol Office at 484-628-8193.

Genetic Education

ECOG/ACRIN-EAQ152: A randomized study of pre-disclosure genetic education v. usual care in tumor profiling for advanced cancer and a pilot study of remote genetic counseling for participants with potential germline mutations identified on tumor profiling.

The purpose of this study is to understand the benefits and limitations of web-based genetic education in patients having their tumor tested for genetic changes.

Learn more about the ECOG/ACRIN-EAQ152 trial or call the Protocol Office at 484-628-8193.

Genitourinary

• PROSTATE

NRG-GU002: Phase II-III trial of adjuvant radiotherapy and androgen deprivation following radical prostatectomy with or without adjuvant docetaxel

The purpose of this study is to compare any good and bad effects of using docetaxel along with the radiation therapy and hormone suppression therapy to using radiation and hormone suppression therapy alone in men with a high chance of prostate cancer recurrence after surgically removing the prostate.

Learn more about the NRG-GU002 trial or call the Protocol Office at 484-628-8193.


RTOG-0924: Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: a phase II randomized trial

The purpose of this study is to compare the effects of hormone therapy (androgen deprivation) and radiation therapy to the prostate gland and seminal vesicles with hormone therapy and radiation therapy to the patient’s whole pelvic body area and the prostate cancer to find out which is better.

Learn more about the RTOG-0924 trial or call the Protocol Office at 484-628-8193.


NRG-BR001: A phase I study of stereotactic body radiotherapy (SBRT) for the treatment of multiple metastases

The purpose of this study is to test the safety of giving a few, focused, high doses of radiation (commonly referred to as stereotactic body radiotherapy [SBRT]) to all known sites of cancer within your body. This study will determine the recommended SBRT dose for each of the locations being treated.

Learn more about the NRG-BR001 trial or call the Protocol Office at 484-628-8193.

Gynecologic

• CERVIX

RTOG-0724: Phase III randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy.

The purpose of this study is to compare the effects, good and/or bad, of giving additional chemotherapy after the usual treatment of chemotherapy and radiation for cervical cancer. The standard treatment for this type of cervical cancer is cisplatin chemotherapy plus radiation. The study will determine whether adding chemotherapy with carboplatin and paclitaxel (experimental for this type of cervical cancer) to standard radiation and cisplatin chemotherapy improves survival without increasing side effects.

Learn more about the RTOG-0724 trial or call the Protocol Office at 484-628-8193.


GOG-0263: Randomized phase III clinical trial of adjuvant radiation versus chemo-radiation in intermediate risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy

The purpose of this study is to determine if weekly chemotherapy with cisplatin and simultaneous radiation therapy increases disease-free time compared to radiation therapy alone.

Learn more about the GOG-0263 trial or call the Protocol Office at 484-628-8193.


• ENDOMETRIUM

GOG-0286B: A randomized phase II/III study of paclitaxel/carboplatin/metformin (NSC#91485) versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVB, or recurrent endometrial cancer

The purpose of this study is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating this type of cancer and to find out what side effects are caused by treatment with these drugs.

Learn more about the GOG-0286B trial or call the Protocol Office at 484-628-8193


GOG-0238: A randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus

The main purpose of this study is to compare radiation therapy in combination with weekly treatment with the chemotherapy drug cisplatin to radiation therapy alone (standard treatment) for this type of cancer.

Learn more about the GOG-0238 trial or call the Protocol Office at 484-628-8193.



• FALLOPIAN TUBE, OVARY, PERITONEAL PRIMARY

NRG-GY004: A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

The purpose of this study is to compare the effect on these types of cancer of using either olaparib by itself or the combination of cediranib and olaparib to the usual chemotherapy given for these cancers (carboplatin and paclitaxel; carboplatin and gemcitabine; or carboplatin and pegylated liposomal doxorubicin [PLD]).

Learn more about the NRG-GY004 trial or call the Protocol Office at 484-628-8193.

Head and Neck

RTOG-0920: A phase III study of postoperative radiation therapy (IMRT) +/- cetuximab for locally-advanced resected head and neck cancer

The purpose of this study is to compare the effects, good and/or bad, of radiation therapy alone with radiation therapy and cetuximab to find out which is better.

Learn more about the RTOG-0920 trial or call the Protocol Office at 484-628-8193.


NRG-HN001: Randomized phase II and phase III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein-Barr virus (EBV) deoxyribonucleic acid (DNA)

This study is being done to see how people with this type of cancer respond to different types or levels of chemotherapy, based on a specific viral marker in their blood. This viral marker is called the Epstein Barr virus, (EBV). A more individualized approach to treating this type of cancer might be found using this blood marker.

Learn more about the NRG-HN001 trial or contact the Protocol Office at 484-628-8193

Hematologic

ECOG-E1A11: Randomized phase III trial of bortezomib, lenalidomide and dexamethasone (VRD) versus carfilzomib, lenalidomide, dexamethasone (CRD) followed by limited or indefinite lenalidomide maintenance in patients with newly diagnosed symptomatic multiple myeloma

The purpose of the first part of the study is to compare the effects, good and/or bad, of a combination of carfilzomib, lenalidomide and dexamethasone with another combination of bortezomib, lenalidomide and dexamethasone, to find out which is better. The second part of the study will examine if it is better to continue lenalidomide until the myeloma comes back or limit it for a defined period of two years.

Learn more about the ECOG-E1A11 trial or contact the Protocol Office at 484-628-8193.

Lung

• NON-SMALL CELL

TJU-BR.31: A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Learn more about the TJU-BR.31 trial or contact the Protocol Office at 484-628-8193.


NRG-BR001: A phase I study of stereotactic body radiotherapy (SBRT) for the treatment of multiple metastases

The purpose of this study is to test the safety of giving a few, focused, high doses of radiation (commonly referred to as stereotactic body radiotherapy [SBRT]) to all known sites of cancer within a participant’s body. This study will determine the recommended SBRT dose for each of the locations being treated.

Learn more about the NRG-BR001 trial
or contact the Protocol Office at 484-628-8193.



• SMALL CELL

NRG-CC003: A randomized phase II/III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small cell lung cancer

The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation treatment method. The hippocampus is part of the brain that is important for memory.

Learn more about the NRG-CC003 trial or contact the Protocol Office at 484-628-8193.


RTOG-RTOG 0538/C30610: Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide

The purpose of this study is to compare the effects, good and/or bad, of two different ways to give radiation therapy.

Learn more about the RTOG-RTOG0538/C30610 trial or contact the Protocol Office at 484-628-8193.


RTOG FOUNDATION-RTOG 3505: Randomized, double-blinded phase III trial of cisplatin and etoposide plus thoracic radiation therapy followed by nivolumab/placebo for locally advanced non-small cell lung cancer

The purpose of this study is to see whether or not receiving nivolumab after the usual chemotherapy (cisplatin and etoposide) with radiation will improve survival for patients with non-small cell lung cancer.

Learn more about the RTOG FOUNDATION-RTOG 3505 trial or contact the Protocol Office at 484-628-8193.

Melanoma

ECOG/ACRIN-EA6134: A randomized phase III trial of dabrafenib + trametinib followed by ipilmumab + nivolumab at progression vs. ipilmumab + nivolumab followed by dabrafenib + trametinib at progression in patients with advanced BRAFV600 mutant melanoma

The purpose of this research study is to compare the good and bad effects of immunotherapy followed by BRAF inhibitor therapy when the disease becomes resistant to BRAF inhibitor therapy followed by immunotherapy.

Learn more about the ECOG/ACRIN-EA6134 trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EA6141: Randomized phase II/III study of nivolumab + ipilimumab + sargramostim vs nivolumab + ipilimumab in patients with unresectable stage III or stage IV melanoma

The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab together.

Learn more about the ECOG/ACRIN-EA6141 trial or contact the Protocol Office at 484-628-8193.


SWOG-S1404: A phase III randomized trial comparing physician/patient choice of high dose interferon or ipilimumab to MK-3475 (pembrolizumab) in patients with high risk resected melanoma

The purpose of this study is to compare the effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) to the usual treatment of either interferon alfa-2b or ipilimumab. In this study, participants will get either MK-3475 or a choice of either interferon alfa-2b or ipilimumab.

Learn more about the SWOG-S1404 trial or contact the Protocol Office at 484-628-8193.


SWOG-S1616: A Phase II randomized study of nivolumab with ipilimumab or impilimumab alone in advanced melanoma patient’s refractory to an Anit-PD1 or Anti PD-L1 agent

The purpose of this study is to compare any good or bad effects of using the drug combination of ipilimumab and nivolumab with the use of ipilimumab alone for the treatment of advanced melanoma.

Learn more about the SWOG-1616 trial or contact the Protocol Office at 484-628-8193.

Multiple Metasteses

NRG-BR001: A phase I study of stereotactic body radiotherapy (SBRT) for the treatment of multiple metastases

The purpose of this study is to test the safety of giving a few, focused, high doses of radiation (commonly referred to as stereotactic body radiotherapy [SBRT]) to all known sites of cancer within a participant’s body. This study will determine the recommended SBRT dose for each of the locations being treated.

Learn more about the NRG-BR001 trial or contact the Protocol Office at 484-628-8193.

Non-Treatment Protocols

• CANCER CONTROL

TJU-08D.213: Jefferson Pancreas Tumor Registry (JPTR)

The purpose of this research study is to collect information to determine if pancreas tumors and related conditions tend to occur more frequently in families with a history of the disease and to determine environmental and occupational risk factors to which patients may be exposed.

Learn more about the TJU-08D.213 trial by calling the Protocol Office at 484-628-8193.



• GENETIC COUNSELING

ECOG/ACRIN-EAQ152: A randomized study of pre-disclosure genetic education vs. usual care in tumor profiling for advanced cancer and a pilot study of remote genetic counseling for participants with potential germline mutations identified on tumor profiling.

The purpose of this study is to understand the benefits and limitations of web-based genetic education in patients having their tumor tested for genetic changes.

Learn more about the ECOG/ACRIN-EAQ152 trial or contact the Protocol Office at 484-628-8193.



• REGISTRY

CARIS-TCREG00100V21209: Registry of CARIS Life Sciences® Molecular Intelligence™ Service (biomarker assessment results intended for correlation with cancer clinical outcomes)

The purpose of this research registry is to evaluate your clinical outcomes, and to possibly determine which treatments may be more effective. The registry outcome data will hopefully result in a change in disease treatment and an improvement of care.

Learn more about the CARIS-TCREG00100V21209 trial by calling the Protocol Office at 484-628-8193.


MPR1-MPR1: Patient registry and bio-specimen profiling repository

The purpose of MPR-1 is to do genetic tests on samples of tissue, including tumor tissue, and if available, normal tissue, that have already been removed from the patient’s body in a previous surgery. The main purpose of doing tests on these tissue samples is to find genetic changes associated the type of cancer diagnosed. The information from the genetic tests, along with the patient’s health information, will be used to help find an appropriate treatment trial for the patient, if one becomes available.

Learn more about the MPR1-MPR1 trial or contact the Protocol Office at 484-628-8193.


ECOG/ACRIN-EAY131: Molecular analysis for therapy choice (MATCH)

The purpose of this screening step is to find out if your tumor cells have a gene change, or mutation targeted by one or more of the drugs used in this study. Participants in the screening study that have a gene change or mutation that matches a sub study will be asked to participate in a specific sub study.

Learn more about the ECOG/ACRIN-EAY131 trial or contact the Protocol Office at 484-628-8193.


Johns Hopkins-TBCRC 040: Plasma tumor DNA and pathologic complete response in early-stage, high-risk breast cancer

The purpose of this study is to see if it is possible to use blood samples to predict response to treatment in breast cancer patients receiving preoperative (or neoadjuvant) therapy.

Learn more about the Johns Hopkins-TBCRC 040 trial or contact the Protocol Office at 484-628-8193


• RISK ASSESSMENT

CITY OF HOPE-RA-COH 96144: Molecular genetics studies of cancer patients and their relatives

The purpose of this study is to investigate genetic, biologic and behavioral factors that may contribute to the development of specific cancers and to study how these factors affect the outcome of the disease.

Learn more about the City of Hope-RA-COH 96144 trial by calling the Protocol Office at 484-628-8193.



• TRANSLATIONAL RESEARCH

ECOG-E1Z11: A cohort study to evaluate genetic predictors of aromatase inhibitor musculoskeletal symptoms (AIMSS)

The purpose of this study is to find out what effects, good and/or bad, anastrozole has and whether genes can help explain how anastrozole affects patients. Only remains open to Asian population.

Learn more about the ECOG-E1Z11 trial or contact the Protocol Office at 484-628-8193